Name: Mal-C2-Gly3-EDA-PNU-159682
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPAC Name

(2S,4S)-N-[2-[[2-[[2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]acetyl]amino]acetyl]amino]acetyl]amino]ethyl]-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracene-2-carboxamide

Canonical SMILES

O=C([C@@]1(O)C[C@H](O[C@H]2C[C@@]3([H])[C@]([C@H](C)O2)([H])O[C@]4([H])[C@@H](OC)OCCN43)C5=C(O)C6=C(C(C7=CC=CC(OC)=C7C6=O)=O)C(O)=C5C1)NCCNC(CNC(CNC(CNC(CCN8C(C=CC8=O)=O)=O)=O)=O)=O

InChI

InChI=1S/C46H53N7O18/c1-21-42-24(52-13-14-68-44(67-3)43(52)71-42)15-33(69-21)70-26-17-46(65,16-23-35(26)41(63)37-36(39(23)61)38(60)22-5-4-6-25(66-2)34(22)40(37)62)45(64)48-11-10-47-28(55)18-50-30(57)20-51-29(56)19-49-27(54)9-12-53-31(58)7-8-32(53)59/h4-8,21,24,26,33,42-44,61,63,65H,9-20H2,1-3H3,(H,47,55)(H,48,64)(H,49,54)(H,50,57)(H,51,56)/t21-,24-,26-,33-,42+,43+,44-,46-/m0/s1

Shipping

Room temperature

Mal-C2-Gly3-EDA-PNU-159682 is a specialized compound used in the design of targeted drug delivery systems, particularly for cancer treatment. The compound consists of a malonic acid group, a glycine spacer (Gly3), an ethylenediamine (EDA) linker, and the cytotoxic agent PNU-159682, which is conjugated to the biomolecule. PNU-159682 is a potent inhibitor of certain cellular pathways, and its conjugation to the Mal-C2-Gly3-EDA linker allows for its targeted delivery to specific cells. This strategy enhances the drug’s effectiveness by concentrating its activity on the tumor site while minimizing off-target toxicity, a common limitation in traditional chemotherapy. The targeted release of PNU-159682 in cancer cells results in a more precise and efficient treatment.

In addition to its application in targeted cancer therapy, Mal-C2-Gly3-EDA-PNU-159682 is also being studied for its potential in overcoming drug resistance. Many cancer cells develop resistance to conventional chemotherapeutic agents due to the activation of efflux pumps or other mechanisms. By conjugating PNU-159682 to a targeted delivery system using the Mal-C2-Gly3-EDA linker, the drug can bypass these resistance mechanisms. The conjugate is designed to be selectively internalized by cancer cells that express specific receptors, thereby overcoming resistance and ensuring that the full therapeutic potential of PNU-159682 is realized. This approach offers a promising solution to the challenge of multidrug resistance in oncology.

Mal-C2-Gly3-EDA-PNU-159682 is also being explored in combination therapies, where it can be used alongside other therapeutic agents, such as immune checkpoint inhibitors or targeted monoclonal antibodies. The targeted delivery of PNU-159682 can enhance the overall therapeutic response when combined with other treatments. For example, using this conjugate in combination with immune-modulatory agents could help to sensitize cancer cells to immune attack, improving the effectiveness of immunotherapy. This strategy holds promise for enhancing the outcomes of combination therapies, particularly in cancers that are resistant to single-agent treatments or immunotherapies, and for providing a more durable and effective response in patients.

Catalog	Product Name	CAS
BADC-01417	MC-VC-PAB-DMEA-PNU159682	1178887-17-6
BADC-01357	PNU-159682 carboxylic acid	1204819-92-0
BADC-01358	DMEA-PNU-159682	1799421-48-9
BADC-00033	PNU-159682	202350-68-3
BADC-01424	NH2-VC-PAB-DMEA-PNU159682	2227350-96-9
BADC-01404	PNU159682-EDA	2255344-14-8
BADC-00737	MA-PEG4-VC-PAB-DMEA-PNU159682	2259318-52-8
BADC-00867	Mal-Phe-C4-VC-PAB-DMEA-PNU-159682	2259318-54-0
BADC-00762	DBCO-PEG4-VC-PAB-DMEA-PNU159682	2259318-56-2
BADC-01426	VA-PAB-DMEA-PNU159682	2414872-62-9